Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | ITGAV | P06756 | 17/20 | 0.39 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.35 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21856498 | 1.00 | PDE10A (0.42) | PDE10AITGAVITGB6ITGB3ITGB8 | |
| SCHEMBL25907344 | 0.89 | PDE10A (0.43) | PDE10AITGAVITGB6ITGB3 | |
| SCHEMBL21777742 | 0.83 | ITGAV (0.55) | ITGAVITGB6ITGB3ITGB8 | |
| SCHEMBL21777740 | 0.83 | ITGAV (0.55) | ITGAVITGB6ITGB3ITGB8 | |
| Hydrochloric Acid SCHEMBL21777913 | 0.82 | ITGAV (0.54) | ITGAVITGB6ITGB3ITGB8 | |
| Hydrochloric Acid SCHEMBL21856566 | 0.82 | ITGAV (0.54) | ITGAVITGB6ITGB3ITGB8 | |
| Hydrochloric Acid SCHEMBL21856568 | 0.82 | ITGAV (0.54) | ITGAVITGB6ITGB3ITGB8 | |
| Hydrochloric Acid SCHEMBL21777908 | 0.82 | ITGAV (0.54) | ITGAVITGB6ITGB3ITGB8 | |
| SCHEMBL21767452 | 0.78 | PDE10A (0.44) | PDE10AITGAVITGB6 | |
| SCHEMBL21767449 | 0.78 | PDE10A (0.44) | PDE10AITGAVITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528803-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3844162-B1 | INHIBITORS OF ALPHA V BETA6 INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-3844162-A1 | INHIBITORS OF av beta6 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020081154-A1 | INHIBITORS OF ανβ6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PDE10A 4466/4885ITGAV 3/4885ITGB6 1/4885 |
| US-12528803-B2 | Inhibitors of αvβ6 integrin | ITGB2, ITGB6, ITGA2 | PDE10A 3397/4885ITGAV 10/4885ITGB6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.